Who is sponsoring NCT02769169?

NCT02769169 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT02769169?

Interventions in NCT02769169: Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose.

What condition does NCT02769169 study?

NCT02769169 studies Polypoidal Choroidal Vasculopathy.

Is NCT02769169 still recruiting?

NCT02769169 is currently terminated. Last updated 19 September 2019.

Last reviewed 2019-09-19 · How we verify

NCT02769169

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Terminated Phase 2, PHASE3 Last updated 19 September 2019

What this trial tests

Phase 2, PHASE3 trial testing Lucentis® (Raibizumab) double-dose in Polypoidal Choroidal Vasculopathy in 5 participants. Terminated before completion.

Timeline

1 August 2018

Primary endpoint
12 September 2018

15 December 2018

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2, PHASE3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	5
Start date	1 August 2018
Primary completion	12 September 2018
Estimated completion	15 December 2018
Sites	4 locations across China

Drugs / interventions tested

Lucentis® (Raibizumab) double-dose — full drug profile →
Lucentis® (Raibizumab) regular-dose — full drug profile →

Conditions studied

Polypoidal Choroidal Vasculopathy — all drugs for Polypoidal Choroidal Vasculopathy →

Sponsor

Sun Yat-sen University

Who can join

Adults 50 to 80, any sex, with Polypoidal Choroidal Vasculopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether double-dose Ranibizumab are effective to regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy (PCV).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02769169 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 19 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02769169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing